Connor, Clark & Lunn Investment Management (CC&L)’s Kalaris Therapeutics KLRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$78.8K Buy
2025
Q4
$85.7K Buy